InflaRx Valuation
Is IFRX N undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of IFRX N when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: IFRX N (MX$24.74) is trading below our estimate of fair value (MX$1849.64)
Significantly Below Fair Value: IFRX N is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for IFRX N?
Key metric: As IFRX N barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.
| What is IFRX N's PB Ratio? | |
|---|---|
| PB Ratio | 1x |
| Book | €82.16m |
| Market Cap | €85.85m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 643.7x |
| Enterprise Value/EBITDA | -1.7x |
| PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does IFRX N's PB Ratio compare to its peers?
| Company | Forward PB | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 1.4x | ||
GBIO Generation Bio | 0.9x | 11.5% | US$96.2m |
COYA Coya Therapeutics | 3.5x | -30.1% | US$106.6m |
A950210 Prestige BioPharma | 0.4x | n/a | ₩177.6b |
PYXS Pyxis Oncology | 0.7x | -24.0% | US$105.3m |
IFRX N InflaRx | 1x | 29.2% | Mex$93.0m |
Price-To-Book vs Peers: IFRX N is expensive based on its Price-To-Book Ratio (1x) compared to the peer average (1x).
Price to Book Ratio vs Industry
How does IFRX N's PB Ratio compare vs other companies in the Global Biotechs Industry?
| 85 Companies | Price / Book | Estimated Growth | Market Cap |
|---|---|---|---|
| 85 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Book vs Industry: IFRX N is good value based on its Price-To-Book Ratio (1x) compared to the Global Biotechs industry average (2.3x).
Price to Book Ratio vs Fair Ratio
What is IFRX N's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PB Ratio | 1x |
| Fair PB Ratio | n/a |
Price-To-Book vs Fair Ratio: Insufficient data to calculate IFRX N's Price-To-Book Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
CSPC Pharmaceutical Group
HK$69.4b
An investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical products in the People’s Republic of China, other Asian regions, North America, Europe, and internationally.
1093 N
HK$15.69
7D
0%
1Y
-27.0%
Exact Sciences
US$13.1b
Provides cancer screening and diagnostic test products in the United States and internationally.
EXAS *
US$872.00
7D
0%
1Y
n/a
Zai Lab
US$2.7b
Develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience.
ZLAB N
US$611.50
7D
0%
1Y
n/a